Seeking Alpha's Quant system consistently outperforms the S&P 500 ( SP500 ), driven by powerful computer processing and SA's ...

Eli Lilly has expanded a collaboration with ... against rivals such as Apple and FitBit whose wearable devices have an increasing medical focus with tech like ECG readers. ActiGraph provides ...

US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its ...

Jan 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular ...

After years of preparation, Eli Lilly is on the ... and can link with compatible devices. That includes continuous glucose monitoring systems developed by Lilly's partner Dexcom as well as other ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.

Vertex Pharmaceuticals is an innovative powerhouse with a good stock to buy on the dip. You can look at the momentum for some stocks and have a feeling that it's about to end. Others, though, have ...

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by ...